Conmed Corp (CNMD) Q3 2026 Earnings Call Highlights: Solid Organic Growth Offset
Conmed Corp (CNMD) reported Q3 2026 earnings with global general surgery up 6.4% and orthopedics up 7.2%. U.S. general surgery grew 2%, while U.S. orthopedics declined slightly. CEO Pat Beyer highlighted strong performance in AirSeal and direct smoke evacuation, but noted variability in OEM business. CFO John Gallagher adjusted the organic growth range to 5.5% due to international performance. AirSeal grew in high single-digit to low double-digit range.
How this was made
The 30-second read
Why it matters
The market-relevant updates are the decomposition of organic growth into direct versus OEM dynamics, the U.S. orthopedic commercial reset progress framing (exit 2026 positioned for 1H 2027 growth), and the gross margin expansion outlook despite a Q3 shortfall versus expectations.
Market read
Traders can use the call’s driver-level explanations to reprice the durability of U.S. growth and the likelihood of achieving 2026 gross margin expansion into 2027.
What to watch
Gross margin shortfall drivers include international mix and discrete operations/inventory items, so the sustainability of the 50-100 bps full-year gross margin expansion may be sensitive to mix and one-time operational factors.
Background
The piece summarizes ConMed’s Q3 2026 earnings call Q&A across general surgery, orthopedics, AirSeal penetration, BioBrace approvals, gross margin drivers, and refinancing/EPS modeling.
Ticker impact
ConMed’s Q3 call highlights organic growth drivers, U.S. orthopedic/commercial changes, AirSeal uptake, and gross margin outlook for 2026-2027.
Likely modest support as investors focus on improving multi-year growth trends and gross margin expansion expectations, offset by ongoing OEM Buffalo Filter variability and U.S. orthopedic near-term weakness.
The article provides specific operational drivers (AirSeal strength, OEM Buffalo Filter drag, distributor onboarding) and guidance framing (gross margin expansion 50-100 bps, EPS flat with GI headwind not repeating), which can shift expectations for 2026 exit and 2027 growth.
Market effects
Signals continued adoption momentum for minimally invasive surgery and smoke evacuation platforms (AirSeal) versus more variable OEM-distribution models in surgical devices.
Emphasizes international order timing effects and U.S.-specific headwinds, which may influence how investors model regional mix for medical device peers.
Reinforces that distributor-driven international dynamics can create quarter-to-quarter volatility in gross margin and growth visibility.
Counterpoint
Investors may discount the improvement narrative if OEM Buffalo Filter variability persists and U.S. orthopedic growth depends heavily on distributor onboarding timelines.
Key entities
- companyConmed Corp
Discussed Q3 performance drivers, U.S. commercial restructuring, AirSeal/BioBrace progress, OEM Buffalo Filter headwinds, and 2026 gross margin/EPS modeling.
